Optimizing Post-allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib
Latest Information Update: 26 Oct 2023
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma
- Focus Therapeutic Use
- 17 Oct 2023 Status changed from active, no longer recruiting to completed.
- 03 Apr 2023 Planned End Date changed from 1 Feb 2023 to 1 Sep 2023.
- 29 Dec 2022 Planned End Date changed from 1 Nov 2022 to 1 Feb 2023.